S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   322.18 (+0.22%)
AAPL   124.29 (-1.25%)
MSFT   233.19 (-0.03%)
FB   264.52 (-0.50%)
GOOGL   2,073.74 (+0.66%)
AMZN   3,152.50 (-1.31%)
TSLA   728.62 (+4.26%)
NVDA   571.77 (+1.08%)
BABA   249.79 (-1.17%)
CGC   35.68 (+1.05%)
GE   13.12 (+4.21%)
MU   90.91 (+3.04%)
NIO   51.38 (+4.62%)
AMD   86.08 (+1.58%)
T   29.38 (+0.69%)
F   12.02 (+3.44%)
ACB   11.44 (+2.05%)
DIS   199.27 (+1.11%)
BA   227.67 (+7.33%)
NFLX   550.80 (+0.85%)
BAC   36.27 (+2.11%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   322.18 (+0.22%)
AAPL   124.29 (-1.25%)
MSFT   233.19 (-0.03%)
FB   264.52 (-0.50%)
GOOGL   2,073.74 (+0.66%)
AMZN   3,152.50 (-1.31%)
TSLA   728.62 (+4.26%)
NVDA   571.77 (+1.08%)
BABA   249.79 (-1.17%)
CGC   35.68 (+1.05%)
GE   13.12 (+4.21%)
MU   90.91 (+3.04%)
NIO   51.38 (+4.62%)
AMD   86.08 (+1.58%)
T   29.38 (+0.69%)
F   12.02 (+3.44%)
ACB   11.44 (+2.05%)
DIS   199.27 (+1.11%)
BA   227.67 (+7.33%)
NFLX   550.80 (+0.85%)
BAC   36.27 (+2.11%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   322.18 (+0.22%)
AAPL   124.29 (-1.25%)
MSFT   233.19 (-0.03%)
FB   264.52 (-0.50%)
GOOGL   2,073.74 (+0.66%)
AMZN   3,152.50 (-1.31%)
TSLA   728.62 (+4.26%)
NVDA   571.77 (+1.08%)
BABA   249.79 (-1.17%)
CGC   35.68 (+1.05%)
GE   13.12 (+4.21%)
MU   90.91 (+3.04%)
NIO   51.38 (+4.62%)
AMD   86.08 (+1.58%)
T   29.38 (+0.69%)
F   12.02 (+3.44%)
ACB   11.44 (+2.05%)
DIS   199.27 (+1.11%)
BA   227.67 (+7.33%)
NFLX   550.80 (+0.85%)
BAC   36.27 (+2.11%)
S&P 500   3,920.63 (+1.01%)
DOW   31,930.97 (+1.25%)
QQQ   322.18 (+0.22%)
AAPL   124.29 (-1.25%)
MSFT   233.19 (-0.03%)
FB   264.52 (-0.50%)
GOOGL   2,073.74 (+0.66%)
AMZN   3,152.50 (-1.31%)
TSLA   728.62 (+4.26%)
NVDA   571.77 (+1.08%)
BABA   249.79 (-1.17%)
CGC   35.68 (+1.05%)
GE   13.12 (+4.21%)
MU   90.91 (+3.04%)
NIO   51.38 (+4.62%)
AMD   86.08 (+1.58%)
T   29.38 (+0.69%)
F   12.02 (+3.44%)
ACB   11.44 (+2.05%)
DIS   199.27 (+1.11%)
BA   227.67 (+7.33%)
NFLX   550.80 (+0.85%)
BAC   36.27 (+2.11%)
Log in
NASDAQ:PRSC

The Providence Service Competitors

$145.99
-8.55 (-5.53 %)
(As of 02/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$145.58
Now: $145.99
$154.51
50-Day Range
$138.63
MA: $162.74
$182.25
52-Week Range
$40.40
Now: $145.99
$156.30
Volume114,303 shs
Average Volume128,367 shs
Market Capitalization$2.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.84

Competitors

The Providence Service (NASDAQ:PRSC) Vs. LH, DGX, DVA, AMED, CHE, and LHCG

Should you be buying PRSC stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to The Providence Service, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), and LHC Group (LHCG).

Laboratory Co. of America (NYSE:LH) and The Providence Service (NASDAQ:PRSC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Laboratory Co. of America and The Providence Service, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Laboratory Co. of America011402.93
The Providence Service00303.00

Laboratory Co. of America presently has a consensus price target of $235.4667, suggesting a potential downside of 3.27%. The Providence Service has a consensus price target of $152.00, suggesting a potential upside of 4.12%. Given The Providence Service's stronger consensus rating and higher possible upside, analysts clearly believe The Providence Service is more favorable than Laboratory Co. of America.

Profitability

This table compares Laboratory Co. of America and The Providence Service's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Laboratory Co. of America6.79%21.05%8.83%
The Providence Service0.23%17.59%8.74%

Institutional & Insider Ownership

89.3% of Laboratory Co. of America shares are owned by institutional investors. 0.7% of Laboratory Co. of America shares are owned by company insiders. Comparatively, 7.5% of The Providence Service shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Laboratory Co. of America and The Providence Service's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$11.55 billion2.07$823.80 million$11.3221.64
The Providence Service$1.51 billion1.37$970,000.00$1.6588.48

Laboratory Co. of America has higher revenue and earnings than The Providence Service. Laboratory Co. of America is trading at a lower price-to-earnings ratio than The Providence Service, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Laboratory Co. of America has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, The Providence Service has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Summary

Laboratory Co. of America beats The Providence Service on 11 of the 14 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and The Providence Service (NASDAQ:PRSC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Quest Diagnostics and The Providence Service, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09602.40
The Providence Service00303.00

Quest Diagnostics presently has a consensus price target of $129.00, suggesting a potential upside of 10.83%. The Providence Service has a consensus price target of $152.00, suggesting a potential upside of 4.12%. Given Quest Diagnostics' higher possible upside, research analysts clearly believe Quest Diagnostics is more favorable than The Providence Service.

Profitability

This table compares Quest Diagnostics and The Providence Service's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
The Providence Service0.23%17.59%8.74%

Institutional & Insider Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by company insiders. Comparatively, 7.5% of The Providence Service shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Quest Diagnostics and The Providence Service's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.03$858 million$6.5617.74
The Providence Service$1.51 billion1.37$970,000.00$1.6588.48

Quest Diagnostics has higher revenue and earnings than The Providence Service. Quest Diagnostics is trading at a lower price-to-earnings ratio than The Providence Service, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Quest Diagnostics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, The Providence Service has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Summary

Quest Diagnostics beats The Providence Service on 12 of the 14 factors compared between the two stocks.

DaVita (NYSE:DVA) and The Providence Service (NASDAQ:PRSC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for DaVita and The Providence Service, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DaVita04102.20
The Providence Service00303.00

DaVita presently has a consensus price target of $116.40, suggesting a potential upside of 13.23%. The Providence Service has a consensus price target of $152.00, suggesting a potential upside of 4.12%. Given DaVita's higher possible upside, research analysts clearly believe DaVita is more favorable than The Providence Service.

Earnings and Valuation

This table compares DaVita and The Providence Service's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$11.39 billion0.99$810.98 million$5.4019.09
The Providence Service$1.51 billion1.37$970,000.00$1.6588.48

DaVita has higher revenue and earnings than The Providence Service. DaVita is trading at a lower price-to-earnings ratio than The Providence Service, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DaVita and The Providence Service's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DaVita7.32%43.99%5.27%
The Providence Service0.23%17.59%8.74%

Risk & Volatility

DaVita has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, The Providence Service has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Institutional & Insider Ownership

91.7% of DaVita shares are owned by institutional investors. 1.0% of DaVita shares are owned by company insiders. Comparatively, 7.5% of The Providence Service shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

DaVita beats The Providence Service on 9 of the 14 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and The Providence Service (NASDAQ:PRSC) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Institutional and Insider Ownership

85.9% of Amedisys shares are owned by institutional investors. 2.8% of Amedisys shares are owned by company insiders. Comparatively, 7.5% of The Providence Service shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Amedisys and The Providence Service, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amedisys03902.75
The Providence Service00303.00

Amedisys presently has a consensus price target of $274.4615, suggesting a potential downside of 1.17%. The Providence Service has a consensus price target of $152.00, suggesting a potential upside of 4.12%. Given The Providence Service's stronger consensus rating and higher possible upside, analysts plainly believe The Providence Service is more favorable than Amedisys.

Volatility & Risk

Amedisys has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, The Providence Service has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Valuation and Earnings

This table compares Amedisys and The Providence Service's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$1.96 billion4.75$126.83 million$4.4064.31
The Providence Service$1.51 billion1.37$970,000.00$1.6588.48

Amedisys has higher revenue and earnings than The Providence Service. Amedisys is trading at a lower price-to-earnings ratio than The Providence Service, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amedisys and The Providence Service's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amedisys8.22%26.41%12.43%
The Providence Service0.23%17.59%8.74%

Summary

Amedisys beats The Providence Service on 10 of the 14 factors compared between the two stocks.

Chemed (NYSE:CHE) and The Providence Service (NASDAQ:PRSC) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Valuation & Earnings

This table compares Chemed and The Providence Service's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemed$1.94 billion3.90$219.92 million$13.9533.96
The Providence Service$1.51 billion1.37$970,000.00$1.6588.48

Chemed has higher revenue and earnings than The Providence Service. Chemed is trading at a lower price-to-earnings ratio than The Providence Service, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

86.0% of Chemed shares are held by institutional investors. 4.0% of Chemed shares are held by company insiders. Comparatively, 7.5% of The Providence Service shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Chemed and The Providence Service, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemed00103.00
The Providence Service00303.00

Chemed presently has a consensus target price of $535.00, suggesting a potential upside of 13.85%. The Providence Service has a consensus target price of $152.00, suggesting a potential upside of 4.12%. Given Chemed's higher possible upside, research analysts plainly believe Chemed is more favorable than The Providence Service.

Profitability

This table compares Chemed and The Providence Service's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemed13.11%38.13%21.70%
The Providence Service0.23%17.59%8.74%

Volatility & Risk

Chemed has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, The Providence Service has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Summary

Chemed beats The Providence Service on 10 of the 13 factors compared between the two stocks.

The Providence Service (NASDAQ:PRSC) and LHC Group (NASDAQ:LHCG) are both mid-cap consumer discretionary companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares The Providence Service and LHC Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Providence Service$1.51 billion1.37$970,000.00$1.6588.48
LHC Group$2.08 billion3.11$95.73 million$4.4745.82

LHC Group has higher revenue and earnings than The Providence Service. LHC Group is trading at a lower price-to-earnings ratio than The Providence Service, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

The Providence Service has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, LHC Group has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for The Providence Service and LHC Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Providence Service00303.00
LHC Group02702.78

The Providence Service currently has a consensus target price of $152.00, suggesting a potential upside of 4.12%. LHC Group has a consensus target price of $220.00, suggesting a potential upside of 7.57%. Given LHC Group's higher probable upside, analysts clearly believe LHC Group is more favorable than The Providence Service.

Profitability

This table compares The Providence Service and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Providence Service0.23%17.59%8.74%
LHC Group5.00%9.71%6.51%

Institutional & Insider Ownership

91.8% of LHC Group shares are held by institutional investors. 7.5% of The Providence Service shares are held by insiders. Comparatively, 4.8% of LHC Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

LHC Group beats The Providence Service on 9 of the 14 factors compared between the two stocks.


The Providence Service Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.6$244.99-0.9%$24.07 billion$11.55 billion28.52
Quest Diagnostics logo
DGX
Quest Diagnostics
2.1$116.37-1.0%$15.83 billion$7.73 billion14.38
DaVita logo
DVA
DaVita
2.0$103.07-1.7%$11.08 billion$11.39 billion15.45
Amedisys logo
AMED
Amedisys
1.2$282.96-1.0%$9.20 billion$1.96 billion56.71Analyst Report
Analyst Revision
Chemed logo
CHE
Chemed
2.3$473.69-1.6%$7.67 billion$1.94 billion28.73Earnings Announcement
Dividend Announcement
Analyst Revision
LHC Group logo
LHCG
LHC Group
1.5$204.80-1.2%$6.40 billion$2.08 billion62.25Upcoming Earnings
AMN Healthcare Services logo
AMN
AMN Healthcare Services
1.3$75.86-0.8%$3.54 billion$2.22 billion40.57Earnings Announcement
Analyst Report
Analyst Revision
R1 RCM logo
RCM
R1 RCM
1.6$28.57-2.1%$3.26 billion$1.19 billion317.48Analyst Revision
MEDNAX logo
MD
MEDNAX
1.4$23.56-2.4%$1.97 billion$3.51 billion-2.73Earnings Announcement
CorVel logo
CRVL
CorVel
0.8$105.00-2.6%$1.83 billion$592.22 million46.67Insider Selling
Tivity Health logo
TVTY
Tivity Health
1.0$23.93-2.4%$1.19 billion$1.13 billion-2.16News Coverage
Cross Country Healthcare logo
CCRN
Cross Country Healthcare
1.1$10.05-5.3%$357.60 million$822.22 million-19.33Analyst Report
Gap Down
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.6$4.07-4.2%$15.82 million$24.08 million-0.48Gap Down
This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.